Mesoblast Ltd (MEOBF)

Currency in USD
1.450
0.000(0.00%)
Closed·
MEOBF is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.4501.450
52 wk Range
0.9105.340
Key Statistics
Prev. Close
1.45
Open
1.45
Day's Range
1.45-1.45
52 wk Range
0.91-5.34
Volume
-
Average Volume (3m)
1.2K
1-Year Change
40.78%
Book Value / Share
0.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
MEOBF Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Mesoblast Ltd News & Analysis

Show more

Mesoblast Ltd Company Profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Compare MEOBF to Peers and Sector

Metrics to compare
MEOBF
Peers
Sector
Relationship
P/E Ratio
−23.8x−1.7x−0.7x
PEG Ratio
−4.26−0.010.00
Price/Book
4.1x5.7x2.6x
Price / LTM Sales
141.1x19.1x3.4x
Upside (Analyst Target)
-242.5%37.8%
Fair Value Upside
Unlock7.0%4.3%Unlock

Earnings

Latest Release
Aug 28, 2025
EPS / Forecast
-0.04 / -0.04
Revenue / Forecast
13.20M / 15.58M
EPS Revisions
Last 90 days

MEOBF Income Statement

People Also Watch

16.950
TLX
+2.73%
2.810
PLS
+2.55%
220.41
CSL
+1.26%
4.860
DRO
+8.72%

FAQ

What Stock Exchange Does Mesoblast Ltd Trade On?

Mesoblast Ltd is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Mesoblast Ltd?

The stock symbol for Mesoblast Ltd is "MEOBF."

What Is the Mesoblast Ltd Market Cap?

As of today, Mesoblast Ltd market cap is 2.42B.

What Is Mesoblast Ltd's Earnings Per Share (TTM)?

The Mesoblast Ltd EPS (TTM) is -0.08.

When Is the Next Mesoblast Ltd Earnings Date?

Mesoblast Ltd will release its next earnings report on 25 Nov 2025.

From a Technical Analysis Perspective, Is MEOBF a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Mesoblast Ltd Stock Split?

Mesoblast Ltd has split 0 times.

How Many Employees Does Mesoblast Ltd Have?

Mesoblast Ltd has 81 employees.

What is the current trading status of Mesoblast Ltd (MEOBF)?

As of 21 Oct 2025, Mesoblast Ltd (MEOBF) is trading at a price of 1.450, with a previous close of 1.45. The stock has fluctuated within a day range of 1.450 to 1.450, while its 52-week range spans from 0.910 to 5.340.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.